Used in cancer immunotherapy to enhance T-cell activation by blocking the LAG-3 (lymphocyte-activation gene 3) receptor, which is an immune checkpoint protein. By inhibiting LAG-3, the antibody helps restore T-cell function and improves the body's ability to detect and destroy tumor cells. It is particularly effective in combination with PD-1 inhibitors, showing promising results in treating advanced melanoma and other solid tumors. Currently utilized in clinical research and therapeutic development for immune-oncology applications.